Fatigue, a mysterious and debilitating symptom for many with primary biliary cholangitis (PBC), has long been a puzzle for medical professionals. But recent research is offering a glimmer of hope and a potential path forward. The spotlight is on elafibranor, a PPAR α/δ agonist, and its intriguing impact on fatigue-related pathways.
In a study presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2025, Dr. Mark Swain and his team revealed a significant association between elafibranor treatment and changes in the expression of ten key proteins. These proteins are believed to play a role in fatigue and mitochondrial function, and their expression levels correlated strongly with the severity of fatigue in PBC patients.
But here's where it gets controversial: the study suggests that elafibranor, by modulating these proteins, may beneficially impact fatigue-associated pathways linked to mitochondrial function. In other words, this drug could be a game-changer for managing fatigue in PBC, offering a new avenue for treatment and improved quality of life.
The research team analyzed serum samples from patients in the phase 3 ELATIVE trial, looking at protein expression changes before and after elafibranor treatment. They found that the expression of these proteins was not only correlated with each other but also with the improvement in fatigue symptoms.
For instance, in patients with moderate to severe fatigue at the start of the trial, the expression of proteins like CA5A, ECI1, and SOD2 was significantly correlated with fatigue severity. And when these patients were treated with elafibranor, the changes in protein expression from baseline to week 52 were strongly correlated with the improvement in fatigue symptoms.
And this is the part most people miss: mitochondrial function, often overlooked, could be a key player in managing fatigue. By targeting PPARα/δ receptors, elafibranor may be influencing the body's energy production and utilization, thus alleviating fatigue.
The study's authors conclude, "Elafibranor treatment led to expression changes of proteins linked to fatigue and mitochondrial function, which correlated with fatigue improvement. This suggests a potential mechanism for the drug's beneficial impact on fatigue in PBC."
So, is this the breakthrough we've been waiting for in managing fatigue in PBC? Could elafibranor be the key to unlocking a new era of treatment? What are your thoughts on this intriguing research? Feel free to share your insights and opinions in the comments below!
